SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cytokinetics, Incorporated ( CYTK)
An SI Board Since April 2004
Posts SubjectMarks Bans Symbol
405 30 0 CYTK
Emcee:  mopgcw Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
355someone bailed/is bailing. fwiw, i bought a large slug here. mopgcw-11/23/2011
354Cytokinetics to Present Clinical Trial Data Relating to CK-2017357 in Patients Wmopgcw-11/23/2011
353Cytokinetics Announces Initiation of Second Cohort of Ongoing Phase II Clinical mopgcw-11/5/2011
352Cytokinetics, Incorporated Reports Third Quarter 2011 Financial Results Thu Octomopgcw-10/30/2011
351 Cytokinetics Announces Strategic Restructuring Tue Omopgcw-10/19/2011
350 Cytokinetics initiated with a Mkt Outperform at Rodman & Renshaw; tgt $4 mopgcw-10/13/2011
349Cytokinetics Announces First Publication on Smooth Muscle Myosin Inhibitors in Tmopgcw-9/28/2011
348SA: Cytokinetics' Promising Pipeline: Value Stock for a Long-Term Investor 2mopgcw-7/20/2011
347indeed, i hate these.mopgcw-6/14/2011
346Stock sale scheme filed for today as price hits all time lows: "Item 1.01 tuck-6/13/2011
345Cytokinetics (CYTK) Completes Phase IIa of CK-2017357 4:01 pm ET 06/02/2011 - Smopgcw-6/13/2011
344Canaccord Genuity Reiterates a 'Buy' on Cytokinetics (CYTK); Phase 2A CKmopgcw-6/13/2011
343Needham & Company Maintains a 'Hold' on Cytokinetics (CYTK); Data frmopgcw-6/13/2011
342As expected, a financing: cytokinetics.com Common, converts, warrants. $20 mituck-4/18/2011
341Cytokinetics Started At Buy By Roth Capital..now we are ready to roll...mopgcw-3/23/2011
340bought another slug here at $1.25...mopgcw-3/17/2011
339and that assigns zero value to the rest of the platform -- which i like for a lomopgcw-2/17/2011
338exactly my thinking as well. at the extremes -- worst case i lose $1.50/sharemopgcw-2/17/2011
337Its a risk/reward call, not a science based conclusion for me. Amgen's upbiofisher-2/17/2011
336"A novel approach to improve cardiac performance: cardiac myosin activatorstuck-2/17/2011
335This is a pretty convincing argument that omecamtiv is a high risk project at betuck-2/16/2011
334It is sure interesting at these levels. But one thing that keeps me from pullintuck-2/16/2011
333me too. Also wrote some puts.biofisher-2/16/2011
332there seems to be some liquidity in the name, someone is selling...mopgcw-2/16/2011
331fwiw, i doubled down here...mopgcw-2/16/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News